Translational COVID-19 vaccine. Safe and efficacious SARS-CoV-2-targeted vaccine
Faculdade de Farmácia da Universidade de Lisboa, Lisboa, Portugal
Currently, there are no specific therapies for COVID-19. The long, asymptomatic incubation period of SARS-CoV-2 has resulted in rapid mass infection across the globe. Vaccines are now crucial to alleviate the present situation.
We are developing a reproducible, biodegradable and safe nano-vaccine rationally designed for concomitant delivery of SARS-CoV-2 epitopes and regulators of immune cell function to generate protective anti-SARS-CoV-2 host responses.
Our extensive previous data on cancer and preliminary findings using SARS-CoV-2 peptides validate our hypothesis that our unique nano-vaccine will upregulate dentritic cell activation/expansion, cytokine release and thereby induce T and B cell immunity.